2. Academic Validation
  3. ARGX-117, a therapeutic complement inhibiting antibody targeting C2

ARGX-117, a therapeutic complement inhibiting antibody targeting C2

  • J Allergy Clin Immunol. 2021 Apr;147(4):1420-1429.e7. doi: 10.1016/j.jaci.2020.08.028.
Inge Van de Walle 1,  Karen Silence 2,  Kevin Budding 3,  Liesbeth Van de Ven 2,  Kim Dijkxhoorn 3,  Elisabeth de Zeeuw 3,  Cafer Yildiz 3,  Sofie Gabriels 2,  Jean-Michel Percier 2,  Johanna Wildemann 3,  Jan Meeldijk 3,  Peter J Simons 4,  Louis Boon 4,  Linda Cox 4,  Rob Holgate 5,  Rolf Urbanus 6,  Henny G Otten 3,  Jeanette H W Leusen 3,  Christophe Blanchetot 2,  Hans de Haard 2,  C Erik Hack 7,  Peter Boross 8
Affiliations

Affiliations

  • 1 argenx BVBA, Zwijnaarde, Belgium. Electronic address: [email protected].
  • 2 argenx BVBA, Zwijnaarde, Belgium.
  • 3 Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • 4 Bioceros BV, Utrecht, The Netherlands.
  • 5 Antitope Ltd, Cambridge, United Kingdom.
  • 6 Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • 7 Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; Prothix BV, Leiden, The Netherlands.
  • 8 Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; Prothix BV, Leiden, The Netherlands. Electronic address: [email protected].
PMID: 32926878 DOI: 10.1016/j.jaci.2020.08.028
Abstract

Background: Activation of the classical and lectin pathway of complement may contribute to tissue damage and organ dysfunction of antibody-mediated diseases and ischemia-reperfusion conditions. Complement factors are being considered as targets for therapeutic intervention.

Objective: We sought to characterize ARGX-117, a humanized inhibitory monoclonal antibody against complement C2.

Methods: The mode-of-action and binding characteristics of ARGX-117 were investigated in detail. Furthermore, its efficacy was analyzed in in vitro complement cytotoxicity assays. Finally, a pharmacokinetic/pharmacodynamic study was conducted in cynomolgus monkeys.

Results: Through binding to the Sushi-2 domain of C2, ARGX-117 prevents the formation of the C3 proconvertase and inhibits classical and lectin pathway activation upstream of C3 activation. As ARGX-117 does not inhibit the alternative pathway, it is expected not to affect the antimicrobial activity of this complement pathway. ARGX-117 prevents complement-mediated cytotoxicity in in vitro models for autoimmune hemolytic anemia and antibody-mediated rejection of organ transplants. ARGX-117 exhibits pH- and calcium-dependent target binding and is Fc-engineered to increase affinity at acidic pH to the neonatal Fc receptor, and to reduce effector functions. In cynomolgus monkeys, ARGX-117 dose-dependently reduces free C2 levels and classical pathway activity. A 2-dose regimen of 80 and 20 mg/kg separated by a week, resulted in profound reduction of classical pathway activity lasting for at least 7 weeks.

Conclusions: ARGX-117 is a promising new complement inhibitor that is uniquely positioned to target both the classical and lectin pathways while leaving the alternative pathway intact.

Keywords

C2; Complement system; complement inhibitor; monoclonal antibody.

Figures
Products